Infasurf Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to high incidence of neonatal respiratory distress syndrome, proven efficacy of surfactant replacement, expansion of nicu facilities, increased survival of premature infants, hospital adoption of surfactant therapy.

The growth in the forecast period can be attributed to rising global preterm births, growth in neonatal healthcare spending, improved access to nicu care, advances in surfactant formulation, expanding neonatal care infrastructure. Major trends in the forecast period include rising use of natural lung surfactants, growth in preterm birth rates, improved neonatal intensive care protocols, early intervention for respiratory distress, standardization of neonatal surfactant therapy.

The rising prevalence of premature births is expected to drive the growth of the Infasurf market in the coming years. Premature birth, defined as the birth of a baby before 37 weeks of gestation, can lead to various health complications, including respiratory issues, developmental delays, and an increased risk of long-term disabilities. Factors such as rising maternal age, higher rates of multiple pregnancies due to assisted reproductive technologies, and chronic health conditions or infections during pregnancy contribute to the rising prevalence of premature births. Infasurf (calfactant) is administered directly into the lungs of premature infants to prevent or treat respiratory distress syndrome (RDS) by reducing surface tension and improving lung function. For instance, in October 2024, a report from the University of Bristol, a UK-based public research university, revealed that about one in 13 births is preterm, totaling over 50,000 cases annually. Despite preventive measures for high-risk women, preterm birth rates continue to rise, thereby contributing to the expansion of the Infasurf market.

Increasing healthcare spending is expected to drive the growth of the Infasurf market in the coming years. Healthcare spending refers to the total financial resources allocated by individuals, governments, private insurers, and other entities towards healthcare services and products. The rise in healthcare spending is driven by factors such as an aging population, advancements in medical technology, the increasing prevalence of chronic diseases, and a growing demand for healthcare services. Infasurf contributes to healthcare spending by reducing the financial burden associated with extended hospital stays and complex respiratory interventions for premature infants with respiratory distress syndrome, ultimately enhancing cost-effectiveness in neonatal care. For instance, in May 2024, the Office for National Statistics, a UK-based government department, reported a 5.6% increase in healthcare spending in the UK between 2022 and 2023, compared with a 0.9% growth in 2022. The total healthcare expenditure in the UK reached around $317.63 billion (£292 billion) in 2023. Therefore, rising healthcare expenditure is playing a key role in driving the growth of the Infasurf market.

The growing awareness of infant respiratory disorders is also expected to propel the growth of the Infasurf market. Infant respiratory disorders encompass a range of conditions affecting newborns' breathing and lung function, often caused by underdeveloped lungs or complications during birth. The increasing prevalence of these disorders is linked to rising premature birth rates, maternal health complications, environmental factors, and higher cesarean delivery rates, along with improvements in detection and diagnosis through advanced medical technologies. Infasurf helps treat infant respiratory disorders by improving lung function and oxygenation in premature infants with respiratory distress syndrome, reducing surface tension in the lungs, and enhancing their ability to expand and exchange gases effectively. For example, in September 2024, the Centers for Disease Control and Prevention (CDC) reported that 58,000 to 80,000 children under the age of 5 are hospitalized annually in the United States due to respiratory syncytial virus (RSV) infection, with infants being at the highest risk. As awareness of infant respiratory disorders rises, the Infasurf market is expected to experience significant growth.

Major companies operating in the infasurf market are ONY Biotech Inc.

North America was the largest region in the infasurf market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infasurf market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the infasurf market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the infasurf market by increasing costs related to bovine raw material sourcing, biologic processing equipment, and cold chain logistics. Neonatal care segments in north america and europe are most affected due to reliance on imported surfactant preparations. These tariffs may increase treatment costs for hospitals and neonatal intensive care units. However, tariffs are encouraging regional manufacturing and strengthening domestic supply chains for critical neonatal respiratory therapies.

The infasurf market research report is one of a series of new reports that provides infasurf market statistics, including infasurf industry global market size, regional shares, competitors with a infasurf market share, detailed infasurf market segments, market trends and opportunities, and any further data you may need to thrive in the infasurf industry. This infasurf market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Infasurf is a natural surfactant primarily used to treat respiratory distress syndrome (RDS) in premature infants. It is a lung surfactant derived from bovine lungs and contains phospholipids, including dipalmitoyl phosphatidylcholine, which help reduce surface tension in the lungs, improving gas exchange.

The main patient demographics for Infasurf include premature infants, full-term infants, and other age groups. Premature infants are babies born before 37 weeks of gestation, often with underdeveloped organs, particularly the lungs. Infasurf is used in premature infants to prevent or treat respiratory distress syndrome by enhancing lung surfactant levels. It is distributed through various channels such as hospitals, specialty clinics, online pharmacies, and retail pharmacies, and is used in the treatment of neonatal respiratory distress syndrome and other respiratory conditions.

The infasurf market consists of sales of infasurf 3 ml intratracheal suspension. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.